Navigation Links
Cancer publishes study confirming disparity in breast cancer treatment
Date:2/16/2010

WILMINGTON, Del.Feb. 16, 2010Cancer, the peer-reviewed international journal of the American Cancer Society, has published a study conducted by HealthCore, Inc. in its Jan. 1 edition, demonstrating disparities in breast cancer treatment between commercially insured African-American and white women.

The HealthCore study reiterates the findings of previous studies conducted in populations using government health programs that African-American women are diagnosed in later stages of the disease.

Breast cancer is the second most common cause of cancer death in white and African-American women in the United States.

"This study demonstrates that disparities in breast cancer care exist even when patients have access to employer-provided healthcare," said Dr. Joe Singer, HealthCore vice president for clinical affairs. "A key takeaway from our study is that African-American women were diagnosed with breast cancer at younger ages, but in later stages of breast cancer, when chances of survival diminish greatly."

The study, funded by Amgen, was conducted in collaboration with Blue Cross and Blue Shield of Georgia and the American Cancer Society. HealthCore is working with Blue Cross and Blue Shield of Georgia and the American Cancer Society to further evaluate the study to understand more about the women who are newly diagnosed with breast cancer so the health plan can determine better ways to communicate with them and their physicians in an attempt to diminish the disparities.

The HealthCore study also found that not all women who tested positive for hormone receptor cancer received anti-estrogen therapy, which is a standard of care set by guidelines established by the National Comprehensive Cancer Network and the American Cancer Society. Of those women who did test positive, white women were more likely than African-American women to receive anti-estrogen therapy.

Specifically, the study found:

  • White women (55.2 percent) were more likely than African- American women (38.4 percent) to be diagnosed with stage 0 or stage I disease.
  • Twice as many African-American women (6.1 percent) compared with white women (3.6 percent) were diagnosed with stage IV disease.
  • Among women who tested positive for hormone receptor cancer, African-American women were less likely to receive treatment, such as aromatase inhibitors or tamoxifen.
  • White women were twice as likely to receive anti-estrogen therapy compared with African-American women, after adjusting for age, cancer stage, and social economic status.

"While treatment for depression and anxiety occurred in both groups, less than half of those women had notes in their medical charts to follow-up with their primary care physician and only one women was referred to a mental health professional," said Dr. Otis Brawley, chief medical officer for the American Cancer Society and study co-author. "Clearly, this is a health intervention needed for both African-American and white women."


'/>"/>

Contact: Lori McLaughlin
lori.mclaughlin2@wellpoint.com
317-407-7403
HealthCore
Source:Eurekalert

Related medicine news :

1. The Icebox of Atlanta Selected as T-shirt Vendor for 3 Major Divisions of American Cancer Society's Relay For Life
2. New therapeutic target for most common solid cancer in childhood?
3. Certain pain medications do not appear to be associated with skin cancer risk
4. NSAIDs Wont Shield Against Skin Cancer
5. PA Breast Cancer Coalition Launches Income Tax Refund Campaign
6. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
7. Advance Toward Test for Aggressive Prostate Cancer
8. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
9. GUMCs Lombardi Hosts Symposium Exploring Future of Cancer Research and Personalized Medicine
10. MRI May Not Add Value to Routine Breast Cancer Care
11. MSU researcher linking breast cancer patients with alternative therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: